Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Fig. 3

a Progression-free survival and b overall survival in patients with relapsed or refractory natural killer/T-cell lymphoma treated with daratumumab. Kaplan–Meier curves are shown for the overall population (all-treated patients; n = 32) and for responders (n = 8) and nonresponders (n = 24). Responses were based on central review. Nonevaluable patients were considered nonresponders

Back to article page
\